Pluri

Innovate. Create. Deliver. Addressing the growing demand for capability and expertise to support the manufacturing of cell therapy products ABOUT TECHNOLOGY​ PARTNERS CONTACT SERVICES SCIENTIFIC PUBLICATIONS ABOUT SERVICES TECHNOLOGY​ PARTNERS SCIENTIFIC PUBLICATIONS CONTACT

Pluri develops and manufactures cell-based products across applications using its advanced cell expansion platforms.

Pluri’s allogeneic MAIT cell platform develops unconventional immune T cells for immunotherapy of solid tumors.

Since 2003, Pluri has advanced cell therapy from preclinical to Phase III clinical development, with expertise in process development and automation.

PluriFood focuses on producing cell-based cultivated food products like meat and fish for sustainable food systems.

Pluri’s methods expand a single placenta cell into billions, enabling allogeneic cell-based therapies for targeted medical treatments.

PluriAgtech uses cell technology to create eco-friendly alternatives for sustainable crop production in agriculture.

Pluri’s cell expansion platform supports ventures across industries by leveraging its patented technology.

Pluri’s Ever After Foods acquires Fishway to bolster its cultivated-protein platform, targeting sustainable seafood alternatives. The move follows a strategic investment aimed at scaling production capabilities. The company focuses on developing lab-grown fish products to meet growing demand for plant-based and cell-cultured proteins.

Aug 2026stockhouseNews article

Pluri’s subsidiary **Cellav** secures UK regulatory approval for its regenerative aesthetics portfolio, enabling market entry in a $900 million annual industry. The registration supports commercial launch and reinforces Pluri’s strategy for international expansion.

Jul 2026BioSpaceNews article

Pluri secures a patent grant in China for its technology in large-scale immune cell expansion, strengthening its intellectual property portfolio. This follows prior U.S. patent approvals, expanding protection across key pharmaceutical markets including the U.S., China, and the Asia-Pacific region. The move bolsters Pluri’s position in developing cell-based therapies.

Feb 2026Yahoo FinanceNews article

Pluri Inc. finishes the initial phase of its **Resbiomed** program, focusing on developing **collagen-rich biomaterials derived from placenta**. The project advances Pluri’s pipeline of regenerative medicine solutions, targeting applications in tissue repair and medical implants. This milestone follows the company’s focus on sustainable, human-derived biomaterials for healthcare applications.

Jan 2026GlobeNewswireNews article